CriticalClass III antiarrhythmic×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). The dronedarone SmPC classifies dronedarone as a class III antiarrhythmic with properties of all four classes, and it also prolongs QTc, by about 10 ms (dronedarone SmPC, EMA). CYP3A4 is the main enzyme that metabolises ranolazine, and ranolazine is a substrate of the transporter P-glycoprotein (P-gp), so inhibitors of either raise its levels (EMA). Dronedarone is a moderate CYP3A4 inhibitor and a strong P-gp inhibitor (dronedarone SmPC, EMA). For comparison, diltiazem, a moderate CYP3A4 inhibitor, raised ranolazine levels 1.5–2.4-fold, and verapamil, a P-gp inhibitor, 2.2-fold (EMA). The documents give no figures for dronedarone.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). QTc prolongation and a slow heart rate are common with dronedarone. Dronedarone's proarrhythmic effect is normally low but may appear with drugs that favour arrhythmias and with electrolyte disorders (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). The US dronedarone label contraindicates such combinations because of the risk of torsade de pointes (dronedarone label, US Food and Drug Administration, FDA). Higher ranolazine levels make its dose-related reactions, such as dizziness and nausea, more likely (ranolazine SmPC, EMA). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine FDA label).
Management
The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with class Ia and class III antiarrhythmics other than amiodarone (ranolazine SmPC, European Medicines Agency, EMA). The dronedarone SmPC classifies dronedarone as a class III antiarrhythmic (dronedarone SmPC, EMA). The US dronedarone label contraindicates drugs that prolong the QT interval and might increase the risk of torsade de pointes (dronedarone label, US Food and Drug Administration, FDA). The ranolazine documents state that ranolazine prolongs the heart-rate-corrected QT interval (QTc) in a dose-related way (EMA; ranolazine FDA label). The European dronedarone SmPC contraindicates drugs that induce torsade de pointes and class I and III antiarrhythmics; its list does not name ranolazine (EMA). The US ranolazine label has no contraindication with antiarrhythmics, but it limits ranolazine to 500 mg twice daily with moderate CYP3A inhibitors. The dronedarone labels describe dronedarone as a moderate inhibitor of this enzyme (ranolazine and dronedarone FDA labels). Dronedarone is contraindicated if the Bazett QTc is 500 ms or more. Monitor the electrocardiogram (ECG) during treatment and stop dronedarone if QTc reaches 500 ms. Correct low potassium and magnesium before and during treatment (dronedarone SmPC, EMA). Use ranolazine with caution in congenital or familial long QT syndrome and known acquired QT prolongation (ranolazine SmPC, EMA). After dronedarone is stopped, it and its metabolite are fully cleared from plasma in about 2 weeks (dronedarone SmPC, EMA), but the documents give no interval before starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5